Healthcare: A Brewing Battleground in Epilepsy

Industry Focus

The Motley Fool

Interview, Money, Consumergoods, Business, Businessnews, Ceo, Technology, Investing, Stocks, Energy, Fool, Financial, Economy, Healthcare, News, Banking, Motley, Tech, Business News, Investments

4.6 • 854 Ratings

🗓️ 18 July 2018

⏱️ 20 minutes

🔗️ Recording | iTunes | RSS

🧾️ Download transcript

Summary

A new spin on an old drug could dent demand for Epidiolex, a marijuana-based epilepsy drug. Plus, here's how important Medicare and Medicaid are to UnitedHealth Group's profits.

Transcript

Click on a timestamp to play from that location

0:00.0	This episode of Industry Focus is brought to you by Sinios Health, a new fully integrated
0:04.8	bio-pharmaceutical solutions organization that's the result of a merger between
0:08.7	Inc research and inventive health. Sinios Health is focused on a simple end goal, shortening the distance from
0:15.3	lab to life. To learn more, visit sinios Health.com.
0:19.3	slash Podcast.
0:20.4	Welcome to Industry Focus, the podcast.
0:23.0	Welcome to Industry Focus, the podcast that dives into a different sector of the stock market every day.
0:28.0	Today is July 18th, and this is the Wednesday health care edition of the show.
0:31.0	I'm your host, Christine Harjus, and I'm joined by health care edition of the show. I'm your host Christine Hargis and I'm joined by health care
0:34.2	specialist Todd Campbell via Skype. We'll kick things off this episode with an update on the
0:39.6	epilepsy drug market, specifically certain types of childhood onset epilepsy that respond
0:45.8	poorly to existing treatment options.
0:49.0	Last month, a company called GW Pharmaceuticals, their ticker is GW pH,
0:53.6	one approval for the first ever marijuana-derived drug,
0:57.5	which was approved to treat Dravett Syndrome
1:00.0	and Lennox-Kestat Syndrome.
1:02.2	We touched on this on our April 25th episode
1:04.6	after the drug got a thumbs up from the FDA's advisory committee.
1:08.3	And then the drug went on to be approved.
1:10.8	It's called Opideolix.
1:12.2	It's actually not yet available for sale because we're
1:14.6	still waiting for it to be scheduled by the Drug Enforcement Administration. And the reason
	...

Please login to see the full transcript.

Previous episode | Next episode

Disclaimer: The podcast and artwork embedded on this page are from The Motley Fool, and are the property of its owner and not affiliated with or endorsed by Tapesearch.

Generated transcripts are the property of The Motley Fool and are distributed freely under the Fair Use doctrine. Transcripts generated by Tapesearch are not guaranteed to be accurate.